MVT-602 is an oligopeptide kisspeptin-1 receptor agonist and an investigational drug candidate for egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).
More than 200 study participants have received treatment with MVT-602 in Phase 1 and Phase 2 clinical trials.
MVT-602 is not approved by the FDA
Clinical Trial Results
MVT-602 is not approved by the FDA.
In October 2018, we presented data from a Phase 1 trial of MVT-602 at the American Society of Reproductive Medicine (ASRM) Scientific Congress. Results of this trial showed that administration of MVT-602 in 24 healthy premenopausal women in the follicular phase produced a dose-related increase in LH and expected post-dose increases in FSH and estrogen. In June 2019, we presented data from a Phase 2a trial of MVT-602 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. Results of this trial showed that the administration of MVT-602 produced an LH surge that approximated the natural mid-cycle LH surge and was associated with high rates of ovulation on ultrasound. Adverse events in these studies were similar between placebo and the MVT-602 groups with no apparent dose-related effects.
Recent News and Presentations
30 Dec 2019
Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
25 Nov 2019
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019